Summit Therapeutics (SMMT) has drawn fresh attention after scrapping a proposed US$500 million underwritten public offering just a day after announcing it, a move linked to funding plans for lead drug ivonescimab.

Against this backdrop, Summit Therapeutics’ share price return has fallen 14.26% over the past 30 days and 17.44% over 90 days. Its 1 year total shareholder return is down 33%, while the 3 year total shareholder return remains very large at over 4x.

If this kind of event driven move has your attention, it may be a good moment to widen your watchlist and check out 38 healthcare AI stocks

With Summit Therapeutics trading well below some valuation estimates but already reflecting big three year gains, investors now face a key question: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 51.2% Undervalued

On the most followed narrative, Summit Therapeutics’ fair value of $29.18 sits well above the last close of $14.25. This puts the current share price against a much higher long term projection built on ivonescimab’s potential.

The breadth of ivonescimab clinical activity across at least 15 Phase III trials and more than 4,000 treated patients positions Summit to participate in the long term shift toward combination immuno oncology and anti angiogenic regimens in multiple tumor types, which is most relevant for potential future revenue growth.

Want to see what sits behind that valuation gap? The narrative leans heavily on aggressive revenue expansion, margin lift from today’s losses, and a much richer future earnings multiple. The real story is in how those moving parts stack together.

Result: Fair Value of $29.18 (UNDERVALUED)

However, Summit Therapeutics’ single drug focus and heavy R&D spending, combined with unresolved FDA decisions on HARMONi, could quickly challenge this undervalued narrative.

Next Steps

With sentiment on Summit Therapeutics clearly split between risks and rewards, it makes sense to move quickly and test the numbers yourself using 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Summit Therapeutics?

If Summit Therapeutics has sharpened your interest, do not stop there. Broaden your watchlist now with focused stock ideas that match different investing goals.

• Target potential mispricings by scanning companies that combine quality fundamentals with attractive valuations through the 44 high quality undervalued stocks.
• Prioritise resilience by reviewing stocks that appear on the 69 resilient stocks with low risk scores, where business strength and risk controls sit front and center.
• Hunt for lesser known opportunities by checking the screener containing 18 high quality undiscovered gems, which highlights companies with solid metrics that many investors may be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.